A Boston-based insurer with fewer than two thousand staff is on course to be valued higher than most FTSE 100 companies, and the reason has nothing to do with hospitals, drugs or doctors in the conventional sense. Devoted Health, founded in 2017 by two brothers who between them ran the operations of a major American health records firm and served as the White House's chief technology officer, is in talks to raise fresh capital at a £18.3 billion valuation, up from  £12 billion earlier this year. Its membership grew 121 per cent in the year to January, and the engine behind that growth is an in-house artificial intelligence system called Orinoco, which sits across both sides of the business: the insurance plan and the care itself.

What makes Devoted worth studying from a London office rather than a Boston boardroom is not the number. It is the mechanism that produces the number. Because Devoted both insures its members and coordinates their care, every pound, or in this case dollar, spent on better data and earlier intervention comes back to the same balance sheet. Investors are not simply betting on artificial intelligence in healthcare in the abstract. They are betting on a structure where the financial incentive to use it well is direct, immediate and impossible to dilute across a dozen separate institutions.

That structure has no real equivalent in Britain, and it would be a mistake to pretend otherwise. The NHS does not underwrite risk in the way a Medicare Advantage insurer does, and nobody serious is proposing that it should start. But the underlying question Devoted's valuation poses, whether an organisation can be trusted to invest heavily in data and automation because it will visibly capture the benefit, is one the NHS is being forced to answer in a far more constrained way this year.

An unpublished planning document circulating between NHS England and the Department of Health and Social Care sets out a £7.4 billion digital investment programme intended to deliver 49 per cent of the productivity targets in the ten-year health plan between 2026 and 2030. The projected returns are substantial on paper, an £8.2 billion four-year benefit rising to £36.6 billion over a decade, driven largely by workflow automation and the ambient voice technology already being rolled out to transcribe clinical conversations, with £200 million committed to that programme alone in its first year. The technology is judged mature enough to be called a "no regrets" priority. The money to scale it, by contrast, is still sitting with the Treasury, which has yet to sign the plan off.

This is the gap that Devoted's fundraising throws into relief. A private American insurer can move from one funding round to the next in a matter of months because a single set of investors owns the entire chain of decision-making, from the capital raised to the care delivered to the savings realised. The NHS, structured around commissioning bodies, individual trusts and a national finance function that must justify every pound against competing claims on the same Spending Review settlement, cannot compress that chain in the same way, however clear the underlying productivity case becomes. Sir Jim Mackey has said as much himself, warning that the health service is "boxed in" by an approach to capital that treats technology investment as a discretionary extra rather than the precondition for the sustainability it is meant to produce.

None of this argues for importing an American insurance model that would sit awkwardly, at best, with a system built on universal coverage free at the point of use. What it does argue for is honesty about why the NHS's own artificial intelligence ambitions move at the pace they do. It is not a shortage of evidence, nor a lack of willing technologists inside trusts already stretched thin by a digital vacancy rate approaching a third of their workforce. It is that nobody inside the NHS captures the return on a well-placed investment the way Devoted's backers expect to. Ahead of the Chancellor's Budget in October, that distinction deserves to be argued in public rather than assumed away in a spending review nobody outside Whitehall will read.